You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

Reframing the Management Approach for Moderate to Severe Atopic Dermatitis

  • Authors: Linda Stein Gold, MD; Peter A. Lio, MD
  • CME / ABIM MOC Released: 3/30/2023
  • Valid for credit through: 3/30/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 1.00 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for global dermatologists, allergists/clinical immunologists, nurse practitioners (NPs), and physician assistants (PAs) involved in the care of patients with atopic dermatitis (dermatologic conditions).

The goal of this activity is for learners to be better able to incorporate new and emerging treatments for moderate to severe AD into practice.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Impact of itch and the effect it has on daily living for patients with moderate to severe AD
    • Clinical data and trial endpoints for biologic agents for moderate to severe AD
  • Have greater competence related to
    • Identifying patients with AD who are candidates for treatment with biologic agents
    • Summarizing rationales for treating moderate to severe AD as a chronic disease
  • Demonstrate greater confidence in their ability to
    • Employ shared decision-making with patients when recommending AD treatments


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Linda Stein Gold, MD

    Director of Clinical Research
    Division Head of Dermatology
    Henry Ford Health System
    Detroit, Michigan

    Disclosures

    Linda Stein Gold, MD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie Inc.; Amgen, Inc.; Arcutis Biotherapeutics, Inc.; Bristol Myers Squibb Company; Dermavant Sciences, Inc.; Galderma Laboratories; Genzyme Corporation; Incyte Corporation; Janssen, L.P.; LEO Pharma, Inc.; Lilly; MC2; Novartis; Ortho Dermatologics; Pfizer, Inc.; Sanofi; Sun Pharmaceutical Industries, Ltd.; UCB
    Speaker or member of speakers bureau for: AbbVie Inc.; Arcutis Biotherapeutics, Inc.; Dermavant Sciences, Inc.; Galderma Laboratories; Genzyme Corporation; Incyte Corporation; Pfizer, Inc.; Sanofi; Sun Pharmaceutical Industries, Ltd.
    Research funding from: AbbVie Inc.; Amgen, Inc.; Arcutis Biotherapeutics, Inc.; Bristol Myers Squibb Company; Dermavant Sciences, Inc.; Galderma Laboratories; Incyte Corporation; Janssen, L.P.; LEO Pharma, Inc.; Lilly; Novartis; Ortho Dermatologics; Pfizer, Inc.; Sun Pharmaceutical Industries, Ltd.; UCB

  • Peter A. Lio, MD

    Clinical Assistant Professor of Dermatology and Pediatrics
    Northwestern University Feinberg School of Medicine
    Founding Director, Chicago Integrative Eczema Center
    Founding Partner, Medical Dermatology Associates of Chicago
    Chicago, Illinois

    Disclosures

    Peter A. Lio, MD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie Inc.; Almirall; Altus Labs; Amyris; AOBiome; Arbonne; ASLAN Pharmaceuticals; Biosciences; Bodewell; Boston Skin Science (KPAway), Bristol Myers Squibb Company; Burt's Bees; Castle Biosciences; Concerto Biosciences; Dermavant Sciences, Inc.; Dermira Inc.; Galderma Laboratories, L.P.; Hyphens Pharma; IntraDerm; Janssen; Johnson & Johnson; Kaleido; Kimberly-Clark; LEO Pharma, Inc.; Level Ex; Lilly; Lipidor; L'Oreal; Menlo Therapeutics; Merck; Micreos Human Health BV; My-Or Diagnostics; Pfizer, Inc.; Pierre Fabre; Realm Therapeutics, Inc.; Regeneron Pharmaceuticals, Inc./Sanofi Genzyme; Sibel, Inc.; SkinFix; Sonica LLC; Theraplex; Unilever; Verrica Pharmaceuticals; YobeeCare
    Speaker or member of speakers bureau for: AbbVie Inc.; Galderma Laboratories; Hyphens Pharma; Incyte Corporation; LEO Pharma, Inc.; Lilly; L'Oreal; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc./Sanofi Genzyme
    Contracted researcher for: AbbVie Inc.; AOBiome; Regeneron Pharmaceuticals, Inc./Sanofi Genzyme
    Royalties from: Theraplex for an OTC product called Theraplex AIM
    Patent beneficiary of: Theraplex for an OTC product called Theraplex AIM
    Stock options from: Altus Labs; Boston Skin Science (KPAway); Concerto Biosciences; LearnSkin; Micreos Human Health BV; YobeeCare

Editor

  • Briana Betz, PhD

    Medical Education Director, Medscape, LLC

    Disclosures

    Briana Betz, PhD, has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

    College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Reframing the Management Approach for Moderate to Severe Atopic Dermatitis

Authors: Linda Stein Gold, MD; Peter A. Lio, MDFaculty and Disclosures

CME / ABIM MOC Released: 3/30/2023

Valid for credit through: 3/30/2024, 11:59 PM EST

processing....

Educational Impact Challenge

The goal of this activity is for learners to be better able to incorporate new and emerging treatments for moderate to severe AD into practice.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print